FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2883399237> ?p ?o ?g. }

• W2883399237 endingPage "1057" @default.
• W2883399237 startingPage "1057" @default.
• W2883399237 abstract "<h3>Importance</h3> An increasing number of cutaneous adverse reactions resulting from use of programmed cell death protein 1 (PD-1) inhibitors have been described, but with relatively little focus to date on the timing of these reactions. <h3>Objective</h3> To determine the timing of cutaneous drug reactions after initiation of PD-1 inhibitor therapy. <h3>Design, Setting, and Participants</h3> This retrospective observational study included patients referred to an academic dermatology clinic by an oncologist from January 1, 2014, through February 28, 2018, with at least 1 skin biopsy specimen of a skin reaction associated with PD-1 inhibitor use. Participants were included if they had a biopsy-proven cutaneous reaction in response to a PD-1 inhibitor used alone or in combination with ipilimumab. <h3>Exposures</h3> All patients included in this study received pembrolizumab, nivolumab, or nivolumab with ipilimumab as immunotherapy for cancer. <h3>Main Outcomes and Measures</h3> The main outcome measure was time to onset of biopsy-proven cutaneous reactions that occurred during or after use of pembrolizumab or nivolumab. <h3>Results</h3> A total of 17 patients (12 men, 5 women; mean [SD] age, 68.6 [11.1] years) were identified who presented with cutaneous adverse reactions associated with PD-1 inhibitor therapy; these reactions included lichenoid dermatitis, bullous pemphigoid, erythema multiforme, eczema, lupus, and sarcoidosis. Twelve patients presented with reactions at least 3 months after beginning pembrolizumab or nivolumab therapy. The skin reactions presented a median (range) of 4.2 months (0.5-38.0 months) after drug initiation. In 5 cases, the cutaneous adverse reactions attributed to the PD-1 inhibitor therapy developed after the drug therapy was terminated. <h3>Conclusions and Relevance</h3> Diverse cutaneous adverse reactions secondary to PD-1 inhibitor use may present with delayed onsets and even after discontinuation of therapy. Dermatologists should be aware of the potential for delayed presentations of cutaneous adverse reactions." @default.
• W2883399237 created "2018-08-03" @default.
• W2883399237 creator A5011640449 @default.
• W2883399237 creator A5012202516 @default.
• W2883399237 creator A5012671311 @default.
• W2883399237 creator A5026844565 @default.
• W2883399237 creator A5061056221 @default.
• W2883399237 creator A5073967328 @default.
• W2883399237 creator A5080451817 @default.
• W2883399237 creator A5086740389 @default.
• W2883399237 date "2018-09-01" @default.
• W2883399237 modified "2023-09-26" @default.
• W2883399237 title "Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy" @default.
• W2883399237 cites W2095327463 @default.
• W2883399237 cites W2125082756 @default.
• W2883399237 cites W2153942285 @default.
• W2883399237 cites W2265285917 @default.
• W2883399237 cites W2329871425 @default.
• W2883399237 cites W2343144688 @default.
• W2883399237 cites W2369700818 @default.
• W2883399237 cites W2487303921 @default.
• W2883399237 cites W2549481046 @default.
• W2883399237 cites W2549697938 @default.
• W2883399237 cites W2560367415 @default.
• W2883399237 cites W2595325983 @default.
• W2883399237 cites W2726507447 @default.
• W2883399237 cites W2746991247 @default.
• W2883399237 cites W2764116502 @default.
• W2883399237 cites W2779503684 @default.
• W2883399237 cites W4242622027 @default.
• W2883399237 cites W4244281033 @default.
• W2883399237 doi "https://doi.org/10.1001/jamadermatol.2018.1912" @default.
• W2883399237 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6143042" @default.
• W2883399237 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30027278" @default.
• W2883399237 hasPublicationYear "2018" @default.
• W2883399237 type Work @default.
• W2883399237 sameAs 2883399237 @default.
• W2883399237 citedByCount "79" @default.
• W2883399237 countsByYear W28833992372018 @default.
• W2883399237 countsByYear W28833992372019 @default.
• W2883399237 countsByYear W28833992372020 @default.
• W2883399237 countsByYear W28833992372021 @default.
• W2883399237 countsByYear W28833992372022 @default.
• W2883399237 countsByYear W28833992372023 @default.
• W2883399237 crossrefType "journal-article" @default.
• W2883399237 hasAuthorship W2883399237A5011640449 @default.
• W2883399237 hasAuthorship W2883399237A5012202516 @default.
• W2883399237 hasAuthorship W2883399237A5012671311 @default.
• W2883399237 hasAuthorship W2883399237A5026844565 @default.
• W2883399237 hasAuthorship W2883399237A5061056221 @default.
• W2883399237 hasAuthorship W2883399237A5073967328 @default.
• W2883399237 hasAuthorship W2883399237A5080451817 @default.
• W2883399237 hasAuthorship W2883399237A5086740389 @default.
• W2883399237 hasBestOaLocation W28833992372 @default.
• W2883399237 hasConcept C121608353 @default.
• W2883399237 hasConcept C126322002 @default.
• W2883399237 hasConcept C16005928 @default.
• W2883399237 hasConcept C167135981 @default.
• W2883399237 hasConcept C197934379 @default.
• W2883399237 hasConcept C2775934546 @default.
• W2883399237 hasConcept C2777701055 @default.
• W2883399237 hasConcept C2779121184 @default.
• W2883399237 hasConcept C2779515644 @default.
• W2883399237 hasConcept C2780030458 @default.
• W2883399237 hasConcept C2780035454 @default.
• W2883399237 hasConcept C2780057760 @default.
• W2883399237 hasConcept C2780439664 @default.
• W2883399237 hasConcept C2780664588 @default.
• W2883399237 hasConcept C2781320243 @default.
• W2883399237 hasConcept C2781433595 @default.
• W2883399237 hasConcept C71924100 @default.
• W2883399237 hasConcept C98274493 @default.
• W2883399237 hasConceptScore W2883399237C121608353 @default.
• W2883399237 hasConceptScore W2883399237C126322002 @default.
• W2883399237 hasConceptScore W2883399237C16005928 @default.
• W2883399237 hasConceptScore W2883399237C167135981 @default.
• W2883399237 hasConceptScore W2883399237C197934379 @default.
• W2883399237 hasConceptScore W2883399237C2775934546 @default.
• W2883399237 hasConceptScore W2883399237C2777701055 @default.
• W2883399237 hasConceptScore W2883399237C2779121184 @default.
• W2883399237 hasConceptScore W2883399237C2779515644 @default.
• W2883399237 hasConceptScore W2883399237C2780030458 @default.
• W2883399237 hasConceptScore W2883399237C2780035454 @default.
• W2883399237 hasConceptScore W2883399237C2780057760 @default.
• W2883399237 hasConceptScore W2883399237C2780439664 @default.
• W2883399237 hasConceptScore W2883399237C2780664588 @default.
• W2883399237 hasConceptScore W2883399237C2781320243 @default.
• W2883399237 hasConceptScore W2883399237C2781433595 @default.
• W2883399237 hasConceptScore W2883399237C71924100 @default.
• W2883399237 hasConceptScore W2883399237C98274493 @default.
• W2883399237 hasIssue "9" @default.
• W2883399237 hasLocation W28833992371 @default.
• W2883399237 hasLocation W28833992372 @default.
• W2883399237 hasLocation W28833992373 @default.
• W2883399237 hasLocation W28833992374 @default.
• W2883399237 hasOpenAccess W2883399237 @default.
• W2883399237 hasPrimaryLocation W28833992371 @default.
• W2883399237 hasRelatedWork W172336605 @default.

• next